Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: a clinical studyMOHAMMEDI, Ismaël; PLOIN, Dominique; DUPERRET, Serge et al.Intensive care medicine (Print). 2003, Vol 29, Num 7, pp 1164-1168, issn 0342-4642, 5 p.Article

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotypeSADER, Helio S; HSIUNG, Andre; FRITSCHE, Thomas R et al.Diagnostic microbiology and infectious disease. 2007, Vol 57, Num 3, pp 341-344, issn 0732-8893, 4 p.Article

Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panelsRHOMBERG, Paul R; JONES, Ronald N.Diagnostic microbiology and infectious disease. 2005, Vol 52, Num 1, pp 67-69, issn 0732-8893, 3 p.Article

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulationJONES, Ronald N; FRITSCHE, Thomas R; MOET, Gary J et al.Diagnostic microbiology and infectious disease. 2008, Vol 61, Num 1, pp 76-79, issn 0732-8893, 4 p.Article

Intervention study of the association of antibiotic utilization measures with control of extended-spectrum β-lactamase (ESBL)-producing bacteriaZHONGGUANG WEN; XIAOYANG WEI; YONGHONG XIAO et al.Microbes and infection. 2010, Vol 12, Num 10, pp 710-715, issn 1286-4579, 6 p.Article

Synergistic effect of polyethylenimine plus piperacillin/tazobactam on clinical Pseudomonas aeruginosa isolates resistant to piperacillin/tazobactamBONFIGLIO, Giovanni.Annals of microbiology. 2006, Vol 56, Num 4, pp 345-348, issn 1590-4261, 4 p.Article

In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British IslesLIVERMORE, D. M; MUSHTAQ, S; JAMES, D et al.International journal of antimicrobial agents. 2003, Vol 22, Num 1, pp 14-27, issn 0924-8579, 14 p.Article

False positive galactomannan Platelia due to piperacillin-tazobactamGERLINGER, M. P; ROUSSELOT, P; RIGAUDEAU, S et al.Médecine et maladies infectieuses. 2012, Vol 42, Num 1, pp 10-14, issn 0399-077X, 5 p.Article

Population pharmacokinetics of piperacillin/tazobactam in neonates and young infantsZHIPING LI; YEWEI CHEN; QIN LI et al.European journal of clinical pharmacology. 2013, Vol 69, Num 6, pp 1223-1233, issn 0031-6970, 11 p.Article

Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lotsMOET, Gary J; WATTERS, Amy A; SADER, Helio S et al.Diagnostic microbiology and infectious disease. 2009, Vol 65, Num 3, pp 319-322, issn 0732-8893, 4 p.Article

Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactamDOS SANTOS, Kênia Valéria; GALUPPO DINIZ, Cláudio; DE CASTRO VELOSO, Luciano et al.Research in microbiology (Paris). 2010, Vol 161, Num 4, pp 268-275, issn 0923-2508, 8 p.Article

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumoniaJOSHI, Manjari; METZLER, Michael; MCCARTHY, Mary et al.Respiratory medicine. 2006, Vol 100, Num 9, pp 1554-1565, issn 0954-6111, 12 p.Article

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infectionsWASAN PATEL, Gita; PATEL, Nimish; LAT, Asma et al.Diagnostic microbiology and infectious disease. 2009, Vol 64, Num 2, pp 236-240, issn 0732-8893, 5 p.Article

Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997―2007)JONES, Ronald N; STILWELL, Matthew G; RHOMBERG, Paul R et al.Diagnostic microbiology and infectious disease. 2009, Vol 65, Num 3, pp 331-334, issn 0732-8893, 4 p.Article

Determination of Free and Total Piperacillin―Tazobactam in Plasma by HPLC-MS-MS: An Adapted Method for NeonatesZHIPING LI; QIN LI; YI WANG et al.Chromatographia (Wiesbaden). 2012, Vol 75, Num 9-10, pp 533-539, issn 0009-5893, 7 p.Article

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolatesLOPEZ-CERERO, L; PICON, E; MORILLO, C et al.Clinical microbiology and infection. 2010, Vol 16, Num 2, pp 132-136, issn 1198-743X, 5 p.Article

Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individualNEWMAN, Diane; SCHEETZ, Marc H; ADEYEMI, Oluwadamilola A et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 10, pp 1734-1739, issn 1060-0280, 6 p.Article

Piperacillin/tazobactam-induced paresthesiaeLAMBOURNE, Jonathan; KITCHEN, Joanne; HUGHES, Claudine et al.The Annals of pharmacotherapy. 2006, Vol 40, Num 5, pp 977-979, issn 1060-0280, 3 p.Article

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patientsVISCOLI, C; COMETTA, A; KERN, W. V et al.Clinical microbiology and infection. 2006, Vol 12, Num 3, pp 212-216, issn 1198-743X, 5 p.Article

Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year reviewPLATSOUKA, E; ZISSIS, N. P; PORTOLOS, J et al.Journal of chemotherapy. 2003, Vol 15, Num 1, pp 27-30, issn 1120-009X, 4 p.Article

A Prospective, Open-Label Noncomparative Study with Piperacillin-Tazobactam Monotherapy as Management of Fever in Patients with Acute LeukemiaFANCI, R; BARTOLOZZI, B; LONGO, G et al.Journal of chemotherapy. 2008, Vol 20, Num 4, pp 492-496, issn 1120-009X, 5 p.Article

Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinationsLIU, Q; RAND, K; DERENDORF, H et al.International journal of antimicrobial agents. 2004, Vol 23, Num 5, pp 494-497, issn 0924-8579, 4 p.Article

An evidence based review of the available antibiotic treatment options for neutropaenic patients and a recommendation for treatment guidelinesGLASMACHER, Axel; VON LILIENFELD-TOAL, Marie.International journal of infectious diseases. 2006, Vol 10, issn 1201-9712, S9-S16, SUP2Conference Paper

Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum β-lactamase-producing organismsREESE, Alicia M; FREI, Christopher R; BURGESS, David S et al.International journal of antimicrobial agents. 2005, Vol 26, Num 2, pp 114-119, issn 0924-8579, 6 p.Article

Killing of Escherichia coli by β-lactams at different inoculaTAM, Vincent H; LEDESMA, Kimberly R; CHANG, Kai-Tai et al.Diagnostic microbiology and infectious disease. 2009, Vol 64, Num 2, pp 166-171, issn 0732-8893, 6 p.Article